Qualigen Therapeutics, Inc. announced that it has entered into a Securities Purchase Agreement with returning investor, Alpha Capital Anstalt to issue an 8% Convertible Debenture in the principal amount of $550,000 and to issue a 5-year common stock purchase warrant to purchase 900,016 shares of common stock of the company at an exercise price of $0.26 per share for the gross proceeds of $550,000 on February 26, 2024. The Debenture would have a maturity date of December 31, 2024 and would be convertible, at any time, and from time to time, at investor?s option, into shares of common stock of the Company, at $0.6111 per share, subject to adjustment as described in the Debenture. The Debenture would accrue interest on its outstanding principal balance at the rate of 8% per annum, which would be payable at maturity.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2799 USD | -0.11% | -3.58% | -49.11% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-49.11% | 1.77M | |
+24.39% | 46.71B | |
+48.83% | 41.8B | |
-1.04% | 41.52B | |
-3.42% | 29.55B | |
+10.55% | 25.78B | |
-21.30% | 19.26B | |
+0.73% | 12.14B | |
-3.03% | 12.08B | |
+26.97% | 11.98B |
- Stock Market
- Equities
- QLGN Stock
- News Qualigen Therapeutics, Inc.
- Qualigen Therapeutics, Inc. announced that it expects to receive $0.55 million in funding from Alpha Capital Anstalt